BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a report issued on Friday morning.
Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Inogen from a hold rating to a buy rating and set a $128.00 price target for the company in a research note on Tuesday, January 9th. Piper Jaffray Companies upgraded Inogen from a neutral rating to an overweight rating in a research note on Tuesday, February 20th. Finally, Needham & Company LLC lifted their price target on Inogen from $125.00 to $150.00 and gave the stock a strong-buy rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Inogen has a consensus rating of Buy and an average target price of $107.29.
Inogen (NASDAQ INGN) opened at $126.37 on Friday. The company has a market capitalization of $2,640.00, a PE ratio of 95.73, a P/E/G ratio of 3.49 and a beta of 1.03. Inogen has a 52 week low of $69.82 and a 52 week high of $134.97.
A number of hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC acquired a new position in Inogen in the fourth quarter valued at approximately $957,000. Gotham Asset Management LLC acquired a new position in Inogen in the fourth quarter valued at approximately $863,000. Jane Street Group LLC acquired a new position in Inogen in the fourth quarter valued at approximately $243,000. Meadow Creek Investment Management LLC boosted its stake in Inogen by 26.0% in the fourth quarter. Meadow Creek Investment Management LLC now owns 2,576 shares of the medical technology company’s stock valued at $307,000 after acquiring an additional 532 shares during the period. Finally, Raymond James & Associates acquired a new position in Inogen in the fourth quarter valued at approximately $244,000. Institutional investors own 99.46% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Inogen (INGN) Stock Rating Upgraded by BidaskClub” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/13/inogen-ingn-stock-rating-upgraded-by-bidaskclub.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.